Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries
08:30 EDT 2 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Gilead Sciences, Inc. (Nasdaq: GILD), together with Mylan Laboratories,
Ranbaxy Laboratories Limited and Strides Arcolab, announced today that
they have entered into agreements to collaborate on promoting access to
high-quality,...
Other Sources for this Article
Gilead Sciences
Nick Francis, +44 208 587 2412 (Media)
Amy
Flood, 650-522-5643 (Media)
Patrick O’Brien, 650-522-1936
(Investors)
More From BioPortfolio on "Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
